Immunoassaying based on the V3 peptide Western blot indicate that HIV-1 group O infection is from ANT-70 and confirmation by a specific ANT-70.

Little is known on the spread of HIV-1 group O viruses in Africa. Studies among HIV-infected individuals from different African countries using an enzyme-linked immunosorbent assay (ELISA) based on the V3 peptide from ANT-70 and confirmation by a specific ANT-70 Western blot indicate that HIV-1 group O infection is present in Cameroon, Gabon and Nigeria. Sequence data on a limited number of samples have confirmed that this strategy can lead to the identification of HIV-1 viruses from group O.

In this report we show serological evidence that group O infection is also present in three different West African countries. We tested sera from Senegal, Niger and Togo. Senegal is situated at the tip of West Africa, Niger is a Sahelian country close to Cameroon but the main economic road is from Abidjan (Côte d'Ivoire) and the exchanges between Cameroon and Niger are very limited. Togo is a small country bordering the sea and close to two important economic countries, Nigeria and Côte d'Ivoire.

In 1990, 1184 prostitutes from Niger were tested for HIV-1 and HIV-2 infection. The overall prevalence was 11.2% (84% (n = 113) were HIV-1-positive, 14% (n = 18) were HIV-2-positive and 2% (n = 3) were positive in their tests; persons who used public programs reported receiving HIV counseling at a higher rate. On the other hand, the data reveal that a fairly high percentage of persons at increased risk had not been tested for HIV infection, and additional effort is needed to identify this at-risk and untested sector of the population.

Almost two-thirds of recent HIV diagnostic tests were obtained from private doctors and hospitals. This fact, coupled with the lower rates of counseling for private providers, underscores the importance of private practitioners being able to deliver appropriate HIV prevention messages, referrals and other services to persons tested for HIV.

Finally, persons who are at increased risk for HIV infection and reside outside of the central cities of metropolitan areas had significantly lower levels of recent diagnostic testing. This may be an important target area for HIV prevention programs.

### Presence of HIV-1 group O infection in West Africa

Two aberrant HIV-1 strains (HIV-1<sub>ANT-70</sub> and HIV-1<sub>MVP-518</sub>) have been isolated from Cameroonian patients [1,2]. These isolates had only 50% homology in the envelope region with other HIV-1 isolates and they were classified as group O. Since then additional HIV-1 group O variants from Cameroonian living in France have been described and some of these group O sera have been shown to be unreactive in some commercial screening assays and can give indeterminate Western blot patterns [3]. Therefore studying the spread of these viruses is important in order to investigate whether strategies for blood screening and serodiagnosis need modification.

Little is known on the spread of HIV-1 group O viruses in Africa. Studies among HIV-infected individuals from different African countries using an enzyme-linked immunosorbent assay (ELISA) based on the V3 peptide from ANT-70 and confirmation by a specific ANT-70 Western blot indicate that HIV-1 group O infection is present in Cameroon, Gabon and Nigeria.

### Table 1. Percentage reporting pretest and post-test counseling by source: respondents receiving diagnostic tests in 1992-1993 (1993 NHIS AIDS Knowledge and Attitudes Supplement).

<table>
<thead>
<tr>
<th></th>
<th>%</th>
<th>95% CI</th>
<th>Obs.</th>
<th>%</th>
<th>95% CI</th>
<th>Obs.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reporting pretest counseling</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>28.4</td>
<td>26.0-30.8</td>
<td>1759</td>
<td>37.7</td>
<td>29.3-46.0</td>
<td>233</td>
</tr>
<tr>
<td>Public source</td>
<td>42.2</td>
<td>38.1-46.4</td>
<td>659</td>
<td>58.0</td>
<td>47.4-68.6</td>
<td>113</td>
</tr>
<tr>
<td>Private source</td>
<td>20.8</td>
<td>18.1-23.5</td>
<td>1100</td>
<td>21.9</td>
<td>12.1-31.6</td>
<td>120</td>
</tr>
<tr>
<td>Reporting post-test counseling</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>14.1</td>
<td>12.6-15.7</td>
<td>1759</td>
<td>27.4</td>
<td>20.4-34.5</td>
<td>233</td>
</tr>
<tr>
<td>Public source</td>
<td>24.2</td>
<td>20.4-28.0</td>
<td>659</td>
<td>40.2</td>
<td>30.1-50.3</td>
<td>113</td>
</tr>
<tr>
<td>Private source</td>
<td>8.6</td>
<td>7.0-10.2</td>
<td>1100</td>
<td>17.5</td>
<td>8.9-16.0</td>
<td>120</td>
</tr>
</tbody>
</table>

### References


### Date of receipt: July 1995; revised: September 1995.
tive for both HIV-1 and HIV-2. All HIV-positive sera were ELISA-positive and confirmed by Western blot with antibodies to at least two envelope proteins. The HIV-positive sera from this survey were screened for antibodies to group O. A total of 2235 sera of Senegalese origin were tested for HIV-1 group O antibodies (808 HIV-1, 248 HIV-2, 31 HIV-1 and HIV-2, 40 indeterminate and 1108 HIV-negative). The sera were collected from prostitutes, pregnant women, sexually transmitted disease patients and AIDS patients from different regions in Senegal. Among the negative sera, 164 were collected between 1989 and 1994 from patients with clinical symptoms of AIDS. The indeterminate sera were selected on the basis of a positive reaction in Genelavia mix ELISA (Diagnostics Pasteur, Marne-la-Coquette, France), negative in the Clonatec (Paris, France) ELISA and indeterminate Western blot patterns (i.e., absence of antibodies to the envelope proteins). From Togo, a total of 878 sera (650 HIV-positive and 228 HIV-negative) collected between 1993 and 1995 in Lome, the capital city, were screened.

All these sera were tested for group O antibodies with an improved ELISA using a combination of V3 peptides from ANT-70 and MVP-5180 (research product; Innogenetics NV, Antwerp, Belgium). Sera reactive by ELISA were retested in a line immunoassay (LIA), in which different biotinylated V3 peptides derived from chimpanzee lentiviruses and the divergent African human immunodeficiency virus type 1 (MVP-5180) from Cameroon. Sera reactive by ELISA and LIA were also retested by Western blot for the presence of antibodies to gpl20 of HIV-1ANIT-70H as previously described [4].

In Niger, two HIV-1-positive sera were reactive in V3 ELISA and reacted in LIA strongly and exclusively with the group O V3 peptides. The sera also reacted with gpl20 of ANT-70 by Western blot which clearly confirms the presence of antibodies to HIV-1 group O. The two prostitutes were both Nigerians. In Senegal, for one serum a similar reaction pattern was observed. The serum was from an asymptomatic Senegalese woman aged 19 years with antibodies to HIV-1. In the samples from Togo, one HIV-positive serum had antibodies exclusively reactive with HIV-1 group O V3 peptides in LIA and also reacted with the gpl20 of ANT-70 by Western blot.

Our data show preliminary serological evidence that HIV-1 group O infection is not restricted to Cameroon or neighbouring countries, such as Gabon and Nigeria, but can also be found in West Africa, even in the most extreme West African country, Senegal. Compared to Cameroon, where a prevalence of 2% has been reported [7], our results suggest that the prevalence of HIV-1 group O infection is very low in West Africa.

The spread of these viruses should be further examined to investigate whether their prevalence increases and to find out whether strategies for blood screening and serodiagnosis need modification.


**References**

Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users relative to homosexual men

The interesting study by Spijkerman et al. [1] identified a higher incidence of syncytium-inducing (SI) phenotype in homosexual men compared with injecting drug users (IDU) and confirmed the faster rate of CD4 decline after a switch in HIV-1 phenotype. If homosexual men have a higher incidence of SI phenotype then it might be expected that progression to AIDS and rate of CD4 decline are more rapid in homosexual men than in IDU.

Evidence from other studies for faster rates of progression to AIDS among homosexual men than among IDU,
ORIGINAL PAPERS

Basic Science

241 Studies of HIV-1 envelope glycoprotein-mediated fusion using a simple fluorescence assay

247 Cytotoxic T-lymphocytes from HIV-infected individuals recognize an activation-dependent, non-polymorphic molecule on uninfected CD4+ lymphocytes
D. Bienzle, M. Small and K.L. Rosenthal

255 Predictive value of viral load measurements in asymptomatic untreated HIV-1 infection: a mathematical model
J.P.A. Ioannidis, J.C. Cappelleri, J.Lau, H.S. Sacks and P.R. Skolnik

Clinical

263 Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy
A.E. Head, G.M. Cox, W.A. Schell, J.A. Barlett and J.R. Perfect

269 Predictors of survival in HIV-infected tuberculous patients

273 Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal HIV transmission

283 Production of plasminogen activator and plasminogen activator inhibitors by alveolar macrophages in control subjects and AIDS patients
E. Angelici, C. Contini, R. Romani, O. Epifano, P. Serra and R. Canipari

Epidemiology and Social

291 Increasing the use of bleach and condoms among injecting drug users in Denver: outcomes of a targeted, community-level HIV prevention program


311 Frontloading: a risk factor for HIV and hepatitis C virus infection among injecting drug users in Berlin
K. Stark, R. Müller, U. Bienzle and I. Guggenmoos-Holzmann

EDITORIAL COMMENTS

335 Relationship between fluconazole dosage regimens and the emergence of fluconazole-resistant Candida albicans
M. Bidwell Goetz

337 Hope for evidence-based HIV/AIDS prevention?
G.J. Hart

CORRESPONDENCE

339 Poststenotic cavitating pneumonia due to Rhodococcus equi in HIV infection G.C. Sutor et al.

340 Symptomatic leiomyomas of the adrenal gland in a woman with AIDS P. Parola et al.

341 Cauterization reactions to trimethoprim-sulphamethazine in AIDS patients treated for Pneumocystis carinii pneumonia A.J.M. van der Ven et al.

342 Diagnostic HIV antibody testing in the United States: the role of private providers and public programs J.E. Anderson et al.

343 Presence of HIV-1 group O infection in West Africa M. Peeters et al.

344 Lower prevalence and incidence of HIV-1 syncytium-inducing phenotype among injecting drug users relative to homosexual men A. Mocroft et al.

345 Cytomegalovirus infection: a possible cause of recurrent transient neurological dysfunction in advanced HIV infection J.L. Klein et al.

346 Evaluating behavioral interventions for HIV prevention W.W. Darrow

348 Identification of a novel HLA-A25-restricted epitope in a conserved region of p24 gag (positions 71-80) P. Kleinerman et al.

350 Evaluation of oligonucleotide probes for the determination of the two major HIV-1 env subtypes in Thailand S. Subbarao et al.

MEETINGS • GUIDANCE FOR AUTHORS • FAST TRACK SUBMISSION FORM